炎症と冠動脈微小血管機能障害に関連したメカニズム 保存されたエジェクション分数による心不全
まとめ
発射分子が保存された心不全 (HFpEF) は炎症と併発症に関連しています. このレビューでは,炎症がHFpEFをどのように誘導するか,冠動脈微小血管機能障害と潜在的な治療法に焦点を当てています.
科学分野:
- 心臓病科
- 免疫学
- 病理生理学
背景:
- 心不全の半分以上には,心不全と保存されたエジェクション分数 (HFpEF) が影響する.
- HFpEFは,高血圧,肥満,糖尿病,CKD,COPDを含む多数の併発症と関連しています.
- HFpEFの病原性は完全に理解されていないため,治療の選択肢は限られている.
研究 の 目的:
- HFpEFにおける炎症と冠動脈微小血管機能障害 (CMD) を関連付ける分子メカニズムをレビューする.
- HFpEFにおけるこれらの炎症経路を標的とした現在の治療戦略について議論する.
主な方法:
- HFpEF,併発症,炎症,CMDに関する研究の文献レビュー.
- 炎症による心筋機能不全に関与する分子経路の分析
- HFpEFの現在の治療方法の統合
主要な成果:
- 併発症は,冠動脈微血管炎によるHFpEFにおける心筋機能不全の要因としてますます認識されています.
- 炎症はHFpEFにおけるCMDの発生と進行において重要な役割を果たします.
- 炎症とCMDに関連するいくつかの治療目標が調査されています.
結論:
- 冠動脈の微小血管炎症は,HFpEFと併発症を結びつける重要なメカニズムである.
- 炎症経路とCMDを標的にすることは,新しいHFpEF治療法にとって有望である.
- 複雑な病原性を解明し,HFpEFの治療戦略を最適化するためにさらなる研究が必要である.
さらに関連する動画
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
2.5K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.6K
関連する概念動画
01:29Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:21Myocarditis I: Introduction
28
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
28
01:26Coronary Artery Disease II: Pathophysiology
33
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
33
01:27Heart Failure I: Introduction
52
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
52
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505